Foresee Pharmaceuticals, Inc. is a clinical stage, specialty pharmaceutical company that leverages its proprietary controlled-release drug delivery system to develop products to treat chronic debilitating diseases.
- (11.Feb.2019) Foresee Pharmaceuticals Enters Exclusive License Agreement With Accord Healthcare
- (26.Nov.2018) Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 Mg (Fp-001) for the Treatment of Advanced Prostate Cancer
- (26.Jul.2018) Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator
- (25.Jun.2018) Foresee Pharmaceuticals Completes Share Underwriting Process Through Public Subscription
- (06.Jun.2018) Foresee Pharmaceuticals Completes Share Underwriting Process Through Competitive Auction
- (05.Jun.2018) Foresee Pharmaceuticals Announces Completion of Patient Enrollment in Phase 3 Trial of LMIS 25 Mg